hy-p1237 Search Results


c type natriuretic peptide cnp  (MedChemExpress)
94
MedChemExpress c type natriuretic peptide cnp
BNP and <t>CNP</t> suppressed the activation of primary adult cardiac fibroblasts. ( A ) The protocol of the in vitro assay. ( B ) Effects of ANP (left), BNP (middle) or CNP (right) (at 1.0 µ M each) against the pro-fibrotic alteration of Ccn2 and Acta2 induced by TGFβ ( n = 5–8). ( C ) Additional effect of LBQ657 (50 µ M) on BNP (left) or CNP (right) (5.0 µ M each) ( n = 6–7). ( D ) Antagonizing actions of P19 (1.0 µ M) on CNP (1.0 µ M) added with LBQ657 (10 µ M) ( n = 6). ( E ) Effects of AP811 (1.0 µ M) on CNP (1.0 µ M) with LBQ657 (10 µ M) ( n = 7). Multiple comparison was performed using one-way ANOVA with Tuckey's post-hoc test. Error bars, SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ANP, atrial <t>natriuretic</t> peptide; BNP, B-type natriuretic peptide; <t>CNP,</t> <t>C-type</t> natriuretic peptide; TGFβ, transforming growth factor β.
C Type Natriuretic Peptide Cnp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hy-p1237/C-Type+Natriuretic+Peptide+(CNP)+(1-22)%2C+human/pmc10834649-91-25-29
Average 94 stars, based on 1 article reviews
c type natriuretic peptide cnp - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


BNP and CNP suppressed the activation of primary adult cardiac fibroblasts. ( A ) The protocol of the in vitro assay. ( B ) Effects of ANP (left), BNP (middle) or CNP (right) (at 1.0 µ M each) against the pro-fibrotic alteration of Ccn2 and Acta2 induced by TGFβ ( n = 5–8). ( C ) Additional effect of LBQ657 (50 µ M) on BNP (left) or CNP (right) (5.0 µ M each) ( n = 6–7). ( D ) Antagonizing actions of P19 (1.0 µ M) on CNP (1.0 µ M) added with LBQ657 (10 µ M) ( n = 6). ( E ) Effects of AP811 (1.0 µ M) on CNP (1.0 µ M) with LBQ657 (10 µ M) ( n = 7). Multiple comparison was performed using one-way ANOVA with Tuckey's post-hoc test. Error bars, SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; TGFβ, transforming growth factor β.

Journal: Frontiers in Cardiovascular Medicine

Article Title: Sacubitril/valsartan attenuates atrial conduction disturbance and electrophysiological heterogeneity with ameliorating fibrosis in mice

doi: 10.3389/fcvm.2024.1341601

Figure Lengend Snippet: BNP and CNP suppressed the activation of primary adult cardiac fibroblasts. ( A ) The protocol of the in vitro assay. ( B ) Effects of ANP (left), BNP (middle) or CNP (right) (at 1.0 µ M each) against the pro-fibrotic alteration of Ccn2 and Acta2 induced by TGFβ ( n = 5–8). ( C ) Additional effect of LBQ657 (50 µ M) on BNP (left) or CNP (right) (5.0 µ M each) ( n = 6–7). ( D ) Antagonizing actions of P19 (1.0 µ M) on CNP (1.0 µ M) added with LBQ657 (10 µ M) ( n = 6). ( E ) Effects of AP811 (1.0 µ M) on CNP (1.0 µ M) with LBQ657 (10 µ M) ( n = 7). Multiple comparison was performed using one-way ANOVA with Tuckey's post-hoc test. Error bars, SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CNP, C-type natriuretic peptide; TGFβ, transforming growth factor β.

Article Snippet: At the same time, a pre-treatment with Atrial Natriuretic Peptide (ANP) (Phoenix Pharmaceuticals, Inc., Burlingame, California, USA), B-type Natriuretic Peptide (BNP) (Bachem, Bubendorf, Switzerland) or C-type Natriuretic Peptide (CNP) (MedChemExpress, Monmouth Junction, New Jersey, USA) at 1.0 or 5.0 μ M was initiated with or without antagonists of their cognate receptors; A71915 (Sigma Aldrich, Burlington, Vermont, USA) antagonizing natriuretic peptide receptor-A (NPR-A); P19 (Phoenix Pharmaceuticals, Inc.) antagonizing natriuretic peptide receptor-B (NPR-B); AP811 (R&D Systems, Minneapolis, Minnesota, USA) antagonizing natriuretic peptide receptor-C (NPR-C), at 1.0 μ M each, as well as LBQ657 (sacubitrilat; Cayman Chemical, Ann Arbor, Michigan, USA) at 10 or 50 μ M. Transforming growth factor β (TGFβ; PeproTech, Cranbury, New Jersey, USA) (1.0 ng/ml) was added 30 min after the application of NPs, followed by another incubation for 24 h. After incubation with the drugs, RNA was extracted from the cultured cells and reverse transcription was performed as described above.

Techniques: Activation Assay, In Vitro, Comparison